JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Barnes, B. J.
Right arrow Articles by Hall, I. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnes, B. J.
Right arrow Articles by Hall, I. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH

Vol. 298, Issue 2, 790-796, August 2001

Induction of Tmolt4 Leukemia Cell Death by 3,3-Disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones: Specificity for Type II Inosine 5'-Monophosphate Dehydrogenase

Betsy J. Barnes, Robert A. Izydore, Ann E. Eakin and Iris H. Hall

Division of Medicinal Chemistry and Natural Products, School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina (B.J.B., A.E.E., I.H.H.); and Department of Chemistry, North Carolina Central University, Durham, North Carolina (R.A.I.)

Inosine 5'-monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo pathway for synthesis of guanine nucleotides, is essential for normal cell proliferation and function. New derivatives of the 1,5-diazabicyclo[3.1.0]hexane-2,4-diones were synthesized and examined for antiproliferative effects and selective inhibition of human IMPDH type II activity. The 3,3-disubstituted-6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones proved to be effective antiproliferative agents in tumor cell lines derived from murine and human leukemias, lymphomas, uterine carcinoma, glioma, and breast effusion with ED50 values (concentration of compound that inhibits 50% of cell growth) ranging from 3.3 to 16 µM. The agents acted as antimetabolites suppressing de novo purine biosynthesis at the key regulatory enzyme IMPDH, resulting in the specific suppression of dGTP pool levels by 19 to 64% and DNA synthesis by 39 to 68%. The derivatives were specific inhibitors of IMPDH type II activity as opposed to type I, acting in a competitive manner with respect to inosine 5'-monophosphate, Ki values of 44.2 to 62 µM. In addition, effects of agents on Tmolt4 cell growth and DNA synthesis could be reversed by coincubation with guanosine. Unlike mycophenolic acid and tiazofurin, the 6,6-pentamethylene-1,5-diazabicyclo[3.1.0]hexane-2,4-diones specifically targeted type II IMPDH, where activity is increased in replicating or neoplastic cells, and did not suppress type I activity, where expression is relatively unaffected by cell proliferation or transformation. Agents were not inhibitors of normal human lung fibroblast cell growth, WI-38, most likely due to the observed isoform selectivity.


0022-3565/01/2982-0790$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.